THERALASE TECHNOLOGIES INC. Financials Theralase Technologies Inc.
Equities
TLT
CA88337V1004
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.16 CAD | -3.03% |
|
0.00% | -8.57% |
| Apr. 24 | Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding | CI |
| Apr. 05 | Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 69.45 | 38.81 | 76.6 | 69.28 | 39.98 | 38.29 | - | - |
| Enterprise Value (EV) 1 | 69.45 | 38.81 | 76.6 | 69.28 | 39.98 | 38.29 | 38.29 | 38.29 |
| P/E ratio | -6.67 x | -7.04 x | -17 x | -12.8 x | -7.95 x | -8 x | -8 x | 8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 72 x | 41.8 x | 98.1 x | 60.8 x | 37.4 x | 23.2 x | 16.8 x | 1.1 x |
| EV / Revenue | 72 x | 41.8 x | 98.1 x | 60.8 x | 37.4 x | 23.2 x | 16.8 x | 1.1 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 3.55 x | 4.23 x | 15.1 x | 21.5 x | - | - | 5.33 x | 3.2 x |
| Nbr of stocks (in thousands) | 204,275 | 204,276 | 204,276 | 216,503 | 228,461 | 239,295 | - | - |
| Reference price 2 | 0.3400 | 0.1900 | 0.3750 | 0.3200 | 0.1750 | 0.1600 | 0.1600 | 0.1600 |
| Announcement Date | 4/29/20 | 5/20/21 | 4/29/22 | 4/26/23 | 3/27/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.964 | 0.9291 | 0.7806 | 1.139 | 1.07 | 1.653 | 2.282 | 34.76 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.414 | -5.599 | -4.411 | -5.235 | -4.571 | -4.228 | -5.023 | 7.471 |
| Net income 1 | -7.414 | -5.599 | -4.411 | -5.235 | -4.571 | -4.228 | -5.023 | 5.491 |
| Net margin | -769.04% | -602.56% | -565.06% | -459.81% | -427.06% | -255.78% | -220.11% | 15.79% |
| EPS 2 | -0.0510 | -0.0270 | -0.0220 | -0.0250 | -0.0220 | -0.0200 | -0.0200 | 0.0200 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/29/20 | 5/20/21 | 4/29/22 | 4/26/23 | 3/27/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.1368 | 0.2138 | 0.2117 | 0.3408 | 0.2606 | 0.3256 | 0.2072 | 0.2189 | 0.2806 | 0.3636 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -1.067 | -1.281 | -1.701 | -1.246 | -1.405 | -0.8832 | - | -1.155 | -1.016 | -0.991 |
| Net income 1 | -1.067 | -1.281 | -1.701 | -1.246 | -1.405 | -0.8832 | - | -1.155 | -1.016 | -0.991 |
| Net margin | -780.24% | -599.23% | -803.88% | -365.54% | -539.2% | -271.28% | - | -527.67% | -361.95% | -272.55% |
| EPS 2 | -0.005000 | -0.007000 | -0.008000 | -0.006000 | -0.006000 | -0.004000 | -0.007000 | -0.005000 | -0.005000 | -0.006000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/29/21 | 4/29/22 | 5/30/22 | 8/29/22 | 11/29/22 | 4/26/23 | 5/30/23 | 8/29/23 | 11/29/23 | 3/27/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -53.5% | -61.1% | -62% | -128% | - | - | -58% | 40% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.1000 | 0.0400 | 0.0200 | 0.0100 | - | - | 0.0300 | 0.0500 |
| Cash Flow per Share 2 | -0.0500 | -0.0200 | -0.0200 | -0.0200 | - | 0.0400 | -0.0200 | 0.0200 |
| Capex 1 | 0.53 | 0.16 | 0.1 | 0.07 | - | 0.2 | 0.2 | 0.2 |
| Capex / Sales | 55.31% | 17.71% | 12.92% | 6.18% | - | 12.1% | 8.76% | 0.58% |
| Announcement Date | 4/29/20 | 5/20/21 | 4/29/22 | 4/26/23 | 3/27/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.16
CAD
Average target price
0.8
CAD
Spread / Average Target
+400.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.57% | 27.97M | |
| -37.75% | 12.3M | |
| +19.38% | 994M | |
| -32.70% | 212M | |
| -35.85% | 74.33M |
- Stock Market
- Equities
- TLT Stock
- Financials Theralase Technologies Inc.
